Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-TIL in Advanced Solid Tumors
NCT07349160Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of metabolically armed tumor-infiltrating lymphocytes in solid tumor (advanced stage), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Adverse Events at 1 year. Started Jan 2026; status: recruiting.
02
Drugs
metabolically armed tumor-infiltrating lymphocytes
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07349160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349160.